Industry
Biotechnology
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Loading...
Open
12.52
Mkt cap
466M
Volume
801K
High
12.69
P/E Ratio
-4.83
52-wk high
22.19
Low
11.94
Div yield
N/A
52-wk low
11.51
Portfolio Pulse from
December 11, 2024 | 12:30 pm
Portfolio Pulse from
November 15, 2024 | 1:00 am
Portfolio Pulse from
November 14, 2024 | 9:15 pm
Portfolio Pulse from
November 12, 2024 | 12:30 pm
Portfolio Pulse from
November 07, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 2:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:54 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 10:32 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.